Tests | Number of patients analyzed | AUC (CI95%) | Optimal threshold | Gray zone of optimal threshold | Patients in gray zone, (number (%)) | Sensitivity (CI95%) | Specificity (CI95%) | PLR | NLR |
---|---|---|---|---|---|---|---|---|---|
ΔCCITREND | 33 | 0.90* (0.80–1.00) | 8% | (5–12%) | 10 (30%) | 87% (67–100%) | 89% (72–100%) | 7.90 | 0.15 |
PPVBASELINE-1 | 19 | 0.49 (0.21–0.77) | 10% | (–Inf to Inf) | 19 (100%) | 33% (0–67%) | 80% (50–100%) | 1.65 | 0.84 |
PPVVT8 | 19 | 0.52 (0.24–0.80) | 9% | (–Inf to Inf) | 19 (100%) | 78% (44–100%) | 40% (10–70%) | 1.30 | 0.56 |
ΔPPV6-8 | 19 | 0.59 (0.31–0.88) | 29% | (17%–Inf) | 16 (84%) | 100% (100–100%) | 40% (10–70%) | 1.67 | 0 |
ΔCCIEEO | 33 | 0.65 (0.46–0.84) | 10% | (−4% to 11%) | 26 (79%) | 33% (13–60%) | 100 (100–100%) | Inf | 0.67 |